A new database of more than 4,000 Alzheimer’s disease patients who have
participated in 11 industry-sponsored clinical trials was released on Friday by
the Coalition Against Major Diseases (CAMD). According to the Critical Path
Institute, which oversees the coalition, "This is the first database of
combined clinical trials to be openly shared by pharmaceutical companies and
made available to qualified researchers around the world. It is also the first
effort of its kind to create a voluntary industry data standard that will help
accelerate new treatment research on brain disease, as patients with other
related brain diseases are expected to be added." CAMD is a formal
consortium of pharmaceutical companies, research foundations and patient
advocacy/voluntary health associations, with advisors from federal agencies.
The non-profit Critical Path Institute (C-Path), led by Dr. Ray Woosley, is
funded by a cooperative agreement with the FDA and a matching grant from
Science Foundation Arizona.